Four Days In, the Out-of-State Medical Rollout Is Exposing Hollow Patient Protections

CT CannaTimes Staff - 10.5.2026

Cannabis consumers are not exactly famously known for driving into Connecticut to buy better cannabis….

For years, the better-known story has run the other direction: Connecticut residents driving to Massachusetts, New York, Rhode Island, Maine, or the legacy market for better prices, better product variety, higher-potency products, concentrates, and a less sterile retail experience. CT Insider reported in 2024 that Connecticut residents were leaving the state to buy cannabis because of price, potency, and product restrictions. One registered Connecticut medical patient told the outlet he had not bought in Connecticut “in a long time.” Another customer said she travels to New York, Massachusetts, and Vermont to avoid Connecticut shops.

So when the Department of Consumer Protection sent out a notice today saying hybrid retailers and dispensary facilities are having trouble uploading out-of-state patient information into Connecticut’s Prescription Monitoring and Reporting System, the obvious question is:

Who exactly is this system supposed to be helping?

Because it sure does not look like Connecticut medical cannabis patients.

Four days after Connecticut opened its medical cannabis program to out-of-state qualifying patients and caregivers, DCP is already telling stores what to do when the state’s reporting system cannot process the information. The Oct. 5 notice says DCP “has been made aware of challenges” retailers and dispensaries are having uploading out-of-state patient information into CPMRS. DCP then tells them to make “reasonable efforts” to report medical cannabis dispensations and, if they cannot locate a prescriber name or DEA number, to document the issue on the registration form.

That is not a small technical footnote.

That is the state admitting, four days into the rollout, that the tracking system does not cleanly handle the new out-of-state medical cannabis lane.

And it gets worse.

DCP’s current out-of-state verification form includes a store-use section with two boxes: “Reported in PMP” and “Not reported in PMP.” It also asks for the “Reason not reported.” The form says it must be retained by the hybrid retailer or dispensary facility for at least three years.

So the practical message is this: if the state system cannot take the out-of-state patient information, document it on a form and keep moving.

That is not how mandatory statewide medical tracking is supposed to work.

DCP’s own public FAQ says Public Act 26-8 requires dispensary facilities and hybrid retailers to record cannabis or medical cannabis products sold to qualifying patients, qualifying out-of-state patients, caregivers, and qualifying out-of-state caregivers in CPMRS. That reporting is supposed to include demographic information, product information, and quantities dispensed.

But by day four, DCP is already telling stores how to handle sales that cannot be entered.

That is the whole problem in one sentence.

Connecticut wrote “protections” for medical cannabis patients into law, then built an implementation system where the protections depend on retailer paperwork, budtender judgment, internal store IDs, and after-the-fact audits.

This is not patient protection. It is administrative improvisation.

And it is happening at the same time DCP removed a key BioTrack classification field.

On Sept. 29, DCP told cannabis establishments that BioTrack would push an update after 10 p.m. on Sept. 30 to “remove all potency driven classification for end products.” DCP said the “classification” column would be removed from the cannabis analytic tracking system. Licensees would remain responsible for complying with laws restricting certain products and potencies to medical patients, and for making sure medical-only products are sold as medical-only.

Read that again.

The state removed the system-level classification field, then told licensees they are still responsible for knowing which products are restricted to medical patients.

That is not a control system. That is DCP handing the steering wheel to every store and hoping everyone drives straight.

And this matters because the Oct. 1 legislative changes were not simple. DCP’s own Oct. 1 notice says certain palliative-use products must be made available exclusively to dispensary facilities and hybrid retailers for at least fourteen days after release to market. Hybrid retailers must then make those products available exclusively to qualifying patients, qualifying out-of-state patients, caregivers, and qualifying out-of-state caregivers for at least fourteen days after each shipment is received.

So Connecticut expanded the medical-access lane to include out-of-state patients at the exact moment the product classification system became less clear.

That is insane.

The state is saying: these products are protected for patients first. But the tracking system no longer centrally delineates potency-driven classification. The stores remain responsible. The pharmacists audit later. The out-of-state forms may or may not upload. If they do not upload, document it locally. If the out-of-state patient has no registration number, create an internal store identifier.

How is that supposed to enforce anything statewide?

How does one store know what an out-of-state patient bought at another store if the sale was not successfully uploaded to CPMRS?

How does DCP track an uptick in medical cannabis sales if some of the new “medical” sales can be marked not reported?

How does the state prove patient-priority products were actually reserved for patients if BioTrack no longer carries the classification field and compliance depends on store-level interpretation?

And most importantly:

How does any of this help Connecticut medical cannabis patients?

Out-of-state reciprocity might help a visiting patient who happens to be in Connecticut and needs cannabis while here. Fine. But that is not the same as helping Connecticut patients. Connecticut patients have been dealing with high prices, limited access, product restrictions, shrinking medical sales, and an adult-use market that has already swallowed the medical program’s identity.

Now DCP has expanded access to the same protected medical lane without showing that the lane is actually protected.

That means Connecticut patients are being asked to share patient-priority products with out-of-state cardholders, while the state’s own system struggles to process those out-of-state transactions.

That is not compassion. That is a policy shell.

This also fits a larger DCP pattern. Connecticut’s comprehensive cannabis regulations were withdrawn. DCP has already taken the position that cannabis testing can continue through policies and procedures. Now, with the out-of-state patient rollout, DCP is again relying on notices, FAQs, sample forms, retailer-retained paperwork, and licensee responsibility instead of a clearly adopted, centralized, enforceable system.

The agency keeps saying it cares about patients.

But the actual system says something else.

The actual system says: we removed classification from BioTrack, we opened out-of-state access, we told stores to make reasonable efforts with CPMRS, we created a “Not reported in PMP” pathway, and we expect retailers to figure it out.

Four days in, Connecticut is already at “fill out the form and explain why it did not upload.”

That is not a mature medical cannabis program.

That is a wreck with a patient-access label slapped on it.

And yes, people should expect to see an uptick in “medical” cannabis sales after this. Not necessarily because Connecticut suddenly became a destination for medical cannabis patients. That idea barely passes the laugh test. Connecticut is surrounded by states with cheaper cannabis, broader product menus, and more developed markets.

The uptick, if it comes, will need to be interrogated.

How much is real Connecticut patient demand?

How much is out-of-state visitor activity?

How much is adult-use demand being routed through out-of-state medical credentials?

How much is being reported cleanly to CPMRS?

How much is sitting on paper forms in stores?

DCP should answer those questions now, not months later after the data is already muddy.

Because the issue is not whether every retailer is doing something wrong. The issue is that DCP built a system where too much depends on retailers doing everything right, manually, under unclear and changing guidance, while the state’s own tracking infrastructure fails to carry the weight of the law.

Connecticut medical cannabis patients were promised protections.

Right now, those protections look practically unenforceable.